Table 2.
Visual acuity and central subfoveal thickness at baseline and monthly up to 6 months in response to initial intravitreal dexamethasone. Mean, median, minimum (Min), maximum (Max), standard deviation (SD), and interquartile range (IQR) are shown for (a) visual acuity (Early Treatment Diabetic Retinopathy Study letters (ETDRS) letters) and (b) central subfoveal thickness (µm) at baseline and 6 months following baseline.
| (a) | |||||||
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | |
| (N = 240) | (N = 144) | (N = 90) | (N = 71) | (N = 107) | (N = 94) | (N = 136) | |
| Absolute visual acuity (ETDRS letters) | |||||||
| Mean (SD) | 56.0 (16.3) | 58.8 (15.8) | 56.8 (18.9) | 57.8 (16.0) | 55.6 (16.4) | 56.2 (14.3) | 57.1 (16.2) |
| Median (IQR) | 58 (23) | 61 (19) | 61 (24) | 60 (20) | 60 (23) | 60 (20) | 60 (24) |
| Change in visual acuity (ETDRS letters) | |||||||
| Mean (SD) | 0 (0) | 2.67 (11.5) | 4.06 (11.2) | 1.62 (12.1) | 1.22 (11.5) | 1.16 (13.8) | 1.18 (11.1) |
| Median (IQR) | 0 (0) | 2.0 (9.3) | 4.0 (12) | 1.0 (9.0) | 2.0 (11) | 1.0 (9.8) | 0 (13) |
| (b) | |||||||
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | |
| (N = 240) | (N = 90) | (N = 55) | (N = 39) | (N = 51) | (N = 54) | (N = 90) | |
| Absolute central sub-foveal thickness (μm) | |||||||
| Mean (SD) | 420 (142) | 324 (102) | 322 (97.6) | 385 (132) | 426 (152) | 432 (138) | 412 (146) |
| Median (IQR) | 400 (170) | 310 (110) | 310 (150) | 390 (200) | 410 (150) | 420 (190) | 390 (180) |
| Change in central sub-foveal thickness (μm) | |||||||
| Mean (SD) | 0 (0) | −114 (147) | −142 (148) | −65.7 (129) | −50.5 (138) | −35.2 (156) | −24.2 (152) |
| Median (IQR) | 0 (0) | −72 (120) | −110 (170) | −48 (100) | −32 (180) | −24 (180) | −12 (140) |